Uninformed Breast Cancer Patients Are Making Treatment Decisions Uninformed Breast Cancer Patients Are Making Treatment Decisions
Women with ductal carcinoma in situ (DCIS) are generally uninformed about their diagnosis and are making uninformed treatment decisions, concludes a Dutch study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer
The SKYSCRAPER-01 study evaluatingtiragolumab plusTecentriq did not meet its co-primary endpoint of progression-free survivalThe other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysisThetiragolumab developmentprogramme continues as planned in non-small cell lung cancer and other cancer typesBasel, 11 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from its phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) tre...
Source: Roche Media News - May 11, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer
The SKYSCRAPER-01 study evaluatingtiragolumab plusTecentriq did not meet its co-primary endpoint of progression-free survivalThe other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysisThetiragolumab developmentprogramme continues as planned in non-small cell lung cancer and other cancer typesBasel, 11 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from its phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) tre...
Source: Roche Investor Update - May 11, 2022 Category: Pharmaceuticals Source Type: news
MRI can help guide women's treatment decisions for DCIS
In women with ductal carcinoma in situ (DCIS), whether they chose local excisio...Read more on AuntMinnie.comRelated Reading:
Video from ISMRM 2022: Katja Pinker-Domenig on breast MRI
MRI double reading can reduce unnecessary biopsies
Breast MRI leads to more follow-up, healthcare costs
MRI, CEDM more accurate to measure post-therapy tumor response
Preoperative MRI benefits women with triple-negative breast cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 10, 2022 Category: Radiology Source Type: news
CHMP recommends EU approval of Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Commi...
Source: Roche Media News - April 22, 2022 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Commi...
Source: Roche Investor Update - April 22, 2022 Category: Pharmaceuticals Source Type: news
DCIS Recurrence Often Represents a New Primary Breast Cancer
(MedPage Today) -- NEW ORLEANS -- A search for biomarkers to predict recurrence of ductal carcinoma in situ (DCIS) instead showed that a substantial fraction of recurrences had genetically distinct features from the primary DCIS, questioning... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 11, 2022 Category: Hematology Source Type: news
Recurrent DCIS Can Be Genetically Distinct From Primary Lesion Recurrent DCIS Can Be Genetically Distinct From Primary Lesion
In more than 10% of cases, when ductal carcinoma in situ recurs in the same breast, the new lesion is genetically district from the original lesion.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer
Ad hoc announcement pursuant to Art.53 LRRoche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancerSKYSCRAPER-02, the firstrandomized study oftiragolumab in extensive stage small-cell lung cancer (ES-SCLC),did not meet its co-primary endpoint of progression-free survivalES-SCLC is a hard-to-treat disease andTecentriq plus chemotherapy remains a standard of careTiragolumab continues to be evaluated in non-small cell lung cancer (NSCLC) and other cancer types through additional phase III trials as plannedBasel, 30 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the p...
Source: Roche Media News - March 30, 2022 Category: Pharmaceuticals Source Type: news
Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer
Ad hoc announcement pursuant to Art.53 LRRoche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancerSKYSCRAPER-02, the firstrandomized study oftiragolumab in extensive stage small-cell lung cancer (ES-SCLC),did not meet its co-primary endpoint of progression-free survivalES-SCLC is a hard-to-treat disease andTecentriq plus chemotherapy remains a standard of careTiragolumab continues to be evaluated in non-small cell lung cancer (NSCLC) and other cancer types through additional phase III trials as plannedBasel, 30 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the p...
Source: Roche Investor Update - March 30, 2022 Category: Pharmaceuticals Source Type: news
Magnetic tracing offers new option for assessing DCIS
Magnetic tracers have emerged as a way to map ductal carcinoma in situ (DCIS...Read more on AuntMinnie.comRelated Reading:
AI helps predict which DCIS patients need to be upstaged
Adding breast density to Tyrer-Cuzick influences risk assessment
High breast density, BMI interact to increase breast cancer risk
Should women over 75 continue to get breast screening?
Screening, socioeconomic status linked to breast cancer mortality (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 10, 2022 Category: Radiology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
New tracer bests FDG for diagnosing liver cancer
PET/CT imaging of hepatocellular carcinoma with an experimental gallium-68-base...Read more on AuntMinnie.comRelated Reading:
Sofie receives nod to start trial for PET tracer
PET imaging lays foundation for new cancer therapies
PET tracer shows promise for diagnosing breast cancer
Sofie submits IND application for pancreatic PET agent
New PET radiotracer more effective at detecting cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 10, 2021 Category: Radiology Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
